<DOC>
	<DOCNO>NCT00119015</DOCNO>
	<brief_summary>Some people nasal allergy symptom continue symptom even treatment nasal steroid spray . The purpose study see patient help add another medication ( montelukast ) treatment compare placebo ( substance look like active medication contain drug ) .</brief_summary>
	<brief_title>The Addition Montelukast Fluticasone Treatment Perennial Allergic Rhinitis</brief_title>
	<detailed_description>Clinicians frequently prescribe oral H1 antihistamine allergic rhinitis patient residual symptom take intranasal steroid . Surprisingly , study investigate combination drug fail show added efficacy H1 receptor intranasal steroid alone . Adding montelukast , leukotriene receptor antagonist , intranasal steroid study placebo control fashion . Wilson colleague , open study patient chronic rhinosinusitis , show benefit add montelukast . The investigator would like recruit perennially allergic subject place fluticasone 2 week . Those subject residual symptom would randomize receive either placebo montelukast addition continue fluticasone additional 2 week . A positive study would support clinical practice would serve preemptive strike manage care plan would allow prescription drug . Hypothesis : The addition montelukast treatment perennially allergic subject intranasal steroid effective relieving symptom placebo .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>A clinical history perennial allergic rhinitis positive skin prick test dust mite , cockroach , mold , cat dog antigen . Willingness subject participate complete study , ability understand purpose trial . Physical sign symptom suggestive renal , hepatic cardiovascular disease . Women childbearing potential pregnant , try become pregnant nursing child . Subjects treat systemic steroid previous 30 day . Subjects treat topical ( inhaled , intranasal intraocular ) steroid , Nasalcrom Opticrom previous 15 day . Subjects treat oral antihistamines/decongestants previous seven day . Subjects treat topical ( intranasal intraocular ) antihistamines/decongestants previous 3 day . Subjects treat immunotherapy escalate dose . Subjects chronic antiasthma medication . Subjects polyps nose significantly displace septum . Subjects incur upper respiratory tract infection within 14 day start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>perennial allergic rhinitis</keyword>
</DOC>